University of Bath
Bath, United Kingdom
Location status: Recruiting
NCT Number: NCT07599683
This project will establish the degree to which adding low-dose galactose to a meal can control blood sugar levels. People will consume standardised glucose drinks (75g glucose, as an oral glucose tolerance test). People will consume these with and without the addition of galactose, and with the addition of another sugar (fructose) for an extra comparison. The investigators will use state-of-the-art labelling methods (dual stable isotope technology) to follow what happens to the glucose that is ingested and understand what happens to sugar being released by the liver and sugar being taken up by other tissues like the muscles. These methods can tell the investigators how the addition of galactose can control blood sugar levels. For example, the galactose could slow down the appearance of glucose from the gut and/or liver released into the blood, or it could increase the disappearance of glucose from the blood into muscles. The investigators will measure the appearance of the label on exhaled breath, which will establish whether ingested sugar is stored, or burned as fuel. The investigators will also explore other potential ways in which galactose might control blood sugar levels by measuring key hormones and metabolites that contribute to blood sugar control (for example, insulin, fatty acids, and incretin hormones which potentiate insulin secretion). This additional evidence of how galactose can control blood sugar levels will provide the understanding required to best make use of this approach across a variety of settings.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Bath, United Kingdom
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
7.5 g galactose
7.5 g fructose
75 g glucose
Time frame: 180 minutes
Difference in glucose concentration incremental area under the curve between treatments over a 180-minute postprandial period.
Time frame: 180 minutes
Difference in plasma glucose kinetics (rate of total glucose appearance, rate of endogenous glucose appearance, rate of exogenous glucose appearance, rate of glucose disappearance and glucose metabolic clearance rate) between treatments over a 180-minute postprandial period.
Time frame: 180 minutes
Difference in oxidative and non-oxidative fate of ingested glucose between treatments over a 180-minute postprandial period.
Time frame: 180 minutes
Difference in glucoregulatory hormone and metabolite incremental area under the curve between treatments over a 180-minute postprandial period, with the following metabolites and hormones:
Insulin, C-peptide Glucagon, Glucose-dependent insulinotropic polypeptide (GIP), Glucagon-like peptide-1 (GLP-1), Non-esterified fatty acids (NEFA), Glycerol, Uric acid, Triacylglycerol. Oxygen saturation, pH, Bicarbonate.
Time frame: 180 minutes
Difference in whole-body carbohydrate and fat oxidation rates between treatments over a 180-minute postprandial period.
Time frame: 180 minutes
Difference in hormone and analyte concentrations during the postprandial period, adjusted for baseline, with the following analytes:
Fructose Galactose Low-density lipoprotein cholesterol High-density lipoprotein cholesterol C-reactive protein Aspartate transaminase Alanine aminotransferase
Contact information is provided by the study sponsor or research team.
Javier T Gonzalez, PhD
CONTACT
Lucy Merrell, PhD
CONTACT
University of Bath
Other
Acronym: GLOWS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06755697
Arthritis, Glucose
Taipei, Taiwan
View Trial DetailsNCT05353322
Behavior, Blood Pressure
New York, United States
View Trial DetailsNCT06930976
Glucose, Immune System and Related Disorders
Nashville, Tennessee, United States
View Trial DetailsNCT05958368
Body Weight, C-reactive Protein
Baton Rouge, Louisiana, United States
View Trial Details